Sigmasporin

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Sigmasporin

Quick Facts

Property Description
Active ingredient Cyclosporine (Ciclosporin)
Form Soft capsule, Oral solution, Injectable form, Ophthalmic emulsion
Pharmacological class Immunosuppressant / Calcineurin Inhibitor
Common use Organ rejection prophylaxis, Autoimmune disease management
Origin Naturally-derived (from the fungus Beauveria nivea)

Identity and Classification

Sigmasporin is a brand name for a medicine containing the active substance Cyclosporine (Ciclosporin). It is definitively categorized as a powerful immunosuppressive agent. This class of medicine is crucial for modulating the activity of the body’s immune system, a function clinically recognized for its ability to prevent aggressive immune responses in specific conditions.

Specifically, Cyclosporine belongs to the pharmacological class of Calcineurin Inhibitors. This classification signifies a highly selective mechanism of action that targets T-lymphocytes, the white blood cells central to the immune attack. Sigmasporin is a prescription-only medication, underscoring the need for specialized medical oversight due to its potency and complex therapeutic index.

Composition and General Purpose

The active ingredient, Cyclosporine, is a unique naturally-derived cyclic polypeptide that was originally isolated from the fungus Beauveria nivea. Its structure dictates that it must be manufactured in specialized dosage forms, including soft capsules and oral solutions (for oral use), or as an injectable form (for intravenous use). The specialized formulations often utilize microemulsion technology to ensure consistent and reliable systemic absorption.

The general purpose of Sigmasporin is to lessen the body’s innate defense reactions. By achieving this controlled immune suppression, the drug is primarily used to promote the long-term acceptance of allogeneic transplanted organs (such as kidney or heart) by preventing the aggressive immune reaction known as rejection. Its ability to stabilize immune activity is also utilized in managing specific autoimmune diseases, confirming its vital role in protecting the body's non-native or native tissues from immune attack.

Regulatory References

  1. Immunosuppressants
  2. Definition of Cyclosporine (NCI Drug Dictionary)
Advertisements

What side effects are possible with Sigmasporin?

Possible side effects and safety information

Sigmasporin (Cyclosporine) is associated with an official safety profile that centers on risks inherent to its immunosuppressive nature and dose-related toxicity, as classified by regulatory authorities (e.g., FDA, EMA).


Adverse Reaction Scope

Category Officially Documented Effects Frequency Classification
Organ Toxicity Renal dysfunction (Nephrotoxicity), Liver dysfunction (Hepatotoxicity) Nephrotoxicity is Very Common (ge 1/10)
Vascular & Metabolic Systemic Hypertension (High blood pressure), Hyperlipidaemia (High blood fats) Hypertension is Very Common (ge 1/10)
Neurological Tremor, Headache, Convulsions, Paraesthesia Tremor is Very Common (ge 1/10)
Other Common Gingival Hyperplasia (gum overgrowth), Hypertrichosis (increased hair growth) Classified as Common (> 1/100 to < 1/10)

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions: The primary serious risks officially documented are the increased susceptibility to serious and opportunistic infections (such as Polyomavirus-Associated Nephropathy or PML) and the development of Malignancies, including lymphomas and skin cancer. Serious, but less frequent, reactions also include Posterior Reversible Encephalopathy Syndrome (PRES) and Thrombotic Microangiopathy (TMA).

Dose- and Duration-Related Patterns: Government documents state explicitly that the risk and severity of Nephrotoxicity and Systemic Hypertension are dose- and duration-dependent.

Population-Specific Cautions: Older adult patients may be at a greater risk due to age-related decline in organ function. For non-transplant indications (e.g., Psoriasis), the drug is officially restricted in patients with uncontrolled hypertension, uncontrolled infection, or existing malignancy.

Safety Monitoring Requirements: Regulatory labeling mandates continuous monitoring of whole blood concentrations, renal function, blood pressure, and serum lipids to manage these documented risks.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official prescribing information for Sigmasporin (Cyclosporine) outlines specific documented manifestations and regulatory requirements for managing a suspected overdose.


Documented Overdose Manifestations

Overdose, which typically occurs with excessively high systemic concentrations, is documented to result in several specific signs. Clinical presentations may include vomiting, headache, drowsiness or fatigue, and rapid heart rate (tachycardia). Visible signs such as the yellowing of the skin or eyes (jaundice) and swelling of the limbs (edema) are also associated with high exposures.

Physiologically, high doses are officially linked to nephrotoxicity (kidney damage) and hepatotoxicity (liver damage). These systemic effects may lead to renal dysfunction and systemic hypertension (high blood pressure).


Emergency Actions and Urgent Care

Immediate medical attention must be sought for any suspected overdose. The required emergency management is primarily symptomatic and supportive treatment because no specific antidote is known for Cyclosporine overdose. Procedures such as hemodialysis or hemoperfusion are generally not effective for enhancing drug elimination.

Specific supportive actions documented in regulatory summaries include ensuring a patent airway, monitoring for and treating shock, managing respiratory insufficiency, and being prepared to anticipate and treat seizures. Continuous hospital monitoring of the patient's status and renal function is required due to the risk of dose-dependent organ damage.

Advertisements

Therapeutic Uses of Sigmasporin

What Sigmasporin Treats: Main Uses and Benefits

The medication is primarily used across several domains involving heightened physiological activity and related functional stress.

Sigmasporin is commonly used to help with managing the immune response that commonly occurs after a solid organ transplant. This application assists with managing the risk of organ rejection and supports the patient during difficult episodes associated with acute or disruptive symptom patterns. It is also applied in addressing severe autoimmune conditions, including the joint pain and stiffness of active Rheumatoid Arthritis and the widespread plaque lesions of severe Psoriasis. Furthermore, it is relevant for easing specific forms of immune-driven kidney dysfunction, like certain Nephrotic Syndromes, and managing refractory skin conditions such as severe Atopic Dermatitis.

The medication supports the patient during symptomatic periods and, in autoimmune conditions, helps ease the overall symptom burden, which contributes to improved comfort. It is applied in clinical settings to control the immune over-activity when symptoms may intensify temporarily.


Quick Fact: Supportive Management for Key Symptom Clusters

Focus Condition Categories
Immune Management Conditions characterized by periods of heightened symptoms
Transplant Support Conditions involving systemic or localized discomfort
Symptom Relief Conditions presenting with disruptive symptom manifestations

Regulatory References

  1. Cyclosporine - StatPearls - NCBI Bookshelf
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Sigmasporin

Official regulatory documents define the strict population boundaries for Sigmasporin (Cyclosporine) use.

Category Official Regulatory Statement
Populations for whom use is allowed Adult transplant recipients (kidney, liver, heart). Adults with severe Rheumatoid Arthritis, severe recalcitrant Psoriasis, Nephrotic Syndrome, or severe Atopic Dermatitis (based on specific regional approvals).
Populations for whom use is contraindicated Patients with known hypersensitivity to cyclosporine or any formulation ingredients. For non-transplant uses, the medicine is contraindicated in patients with uncontrolled hypertension, malignancy (cancer), or abnormal renal function.
Age-related eligibility rules Pediatric Transplant Recipients are approved for use. However, safety and efficacy have not been established for pediatric patients with non-transplant conditions like Rheumatoid Arthritis or Psoriasis. Use in older adults is generally acceptable but requires caution due to a higher likelihood of age-related organ issues.
Pregnancy and lactation eligibility Use during pregnancy is generally not recommended unless the potential benefit clearly outweighs the risk to the fetus. Use is contraindicated or not recommended for nursing mothers due to the transfer of the drug into breast milk.
Eligibility-related restrictions The medicine must only be prescribed by physicians experienced in immunosuppressive therapy. Patients with severe hepatic impairment may require dosage adjustment to maintain eligibility.

Connection to the overall eligibility profile:

Regulatory authorities establish clear absolute contraindications based on hypersensitivity and specific comorbidities, especially for non-transplant uses. Eligibility is conditional, requiring specialized medical oversight and being restricted or not established for certain pediatric groups and lactating women, which strictly delineates the officially permissible user base.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Sigmasporin (Cyclosporine) by its property as an inhibitor of metabolic enzymes and drug transporters. Cyclosporine inhibits the CYP3A enzyme system and transporters like P-glycoprotein (P-gp), leading to increased exposure (AUC and C max) of many co-administered medicinal products.


Official Contraindications and Restrictions

Combinations with other substances are listed as contraindicated due to the high risk of severe outcomes. This includes products that significantly increase plasma concentrations, such as Simvastatin and Atorvastatin, which raise the risk of myopathy. The herbal product St. John's wort is also prohibited, as it is documented to decrease Cyclosporine plasma levels and compromise therapeutic efficacy.

Pharmacodynamic interactions pose restrictions, particularly with Nephrotoxic Agents (e.g., Amphotericin B) due to the documented additive risk for renal toxicity. Furthermore, Live Vaccines are prohibited due to the heightened risk of clinical infection.

For consumables, Grapefruit and Grapefruit Juice must be avoided as they are documented to increase Cyclosporine concentrations.


Administration Constraints

Regulatory information requires that administration of Sigmasporin must be done on a consistent daily schedule with respect to meals to maintain stable systemic drug exposure. Additionally, when co-administered, oral doses of Sirolimus must be separated and given 4 hours after the Sigmasporin dose.

Advertisements

Mechanism of Action

The active molecule, Cyclosporine, enters T-lymphocytes and forms a high-affinity complex with the intracellular protein Cyclophilin A (an immunophilin). This drug-protein complex then acts as a specific inhibitor of the enzyme Calcineurin. This targeted inhibition prevents the chemical activation of the NFAT transcription factor, which must normally enter the cell's nucleus to initiate nuclear gene transcription.

The sequestration of NFAT in the cytoplasm, prevented from entering the nucleus, results in a failure to initiate the transcription of key cytokine genes, most notably Interleukin-2 (IL-2). The absence of IL-2 deprives T-cells of the essential growth signal required for clonal expansion—the rapid multiplication of immune cells. This early molecular step modifies signaling dynamics in pathways associated with T-cell activation.

The interruption of the IL-2-dependent amplification process leads to a systemic selective suppression of T-cell-mediated immunity. The drug's mechanism effectively limits the ability of the adaptive immune system to escalate a response to its full potential, resulting in a systemic reduction of T-cell proliferation by reducing the magnitude of the T-cell-mediated response.

Advertisements

Dosage and Administration Information

Sigmasporin is administered through several officially approved routes depending on the formulation and clinical context. Systemic use is typically achieved using the oral capsules or solution, with an intravenous (IV) concentrate reserved for patients temporarily unable to tolerate oral intake. A topical ophthalmic emulsion is also utilized for specific localized conditions.

For systemic therapy, the total daily dose must always be administered in two equally divided doses twice daily (BID), approximately 12 hours apart. Maintaining a consistent schedule regarding both the time of day and the relationship to meals is a core procedural instruction for proper use. Dosing is highly specific and calculated based on mg/kg of body weight, with the initial range varying significantly across approved uses; for example, transplant prophylaxis often begins with 10 to 15 mg/kg/day, while maximum doses for autoimmune conditions are typically capped at 4 to 5 mg/kg/day.

The oral solution requires mixing, which must be performed using a glass container with compatible fluids such as apple or orange juice. The product is not bioequivalent across all brands and formulations, meaning that any change in the specific capsule or solution requires specialist medical supervision.

Usage over time is either long-term for transplant maintenance, where the initial dose is gradually tapered to a lower level, or time-limited for certain autoimmune conditions. Dose adjustments in all systemic uses are strictly guided by the monitoring of Cyclosporine whole blood concentrations to maintain a standardized therapeutic level.

Advertisements

Recent Clinical Evidence

Research Evidence Overview

The evidence base for Sigmasporin (Cyclosporine) consists of research documented in authoritative sources, including Randomized Controlled Trials (RCTs), systematic reviews, and long-term observational studies.


Evidence for Use in Solid Organ Transplant Prophylaxis

Research has explored the observation of Sigmasporin's effects on the immune system’s response to a transplanted organ, which is known as allograft rejection. Researchers used numerous Randomized Controlled Trials (RCTs), often comparing Sigmasporin against other immunosuppressants or placebo. The primary endpoints researchers examined included the rate of acute rejection episodes, long-term graft survival, and patient survival over specific time intervals. These trials included both adult and pediatric patients undergoing various types of solid organ transplants. Because Sigmasporin is often used in combination with other medications, the data show patterns related to outcomes observed in the combination immunosuppressive regimen. Research describes that studies monitored these outcomes for long durations, often 5 to 10 years, providing context for extended transplant management.


Evidence for Use in Specific Autoimmune Conditions

Sigmasporin was also evaluated in studies examining its application for certain severe autoimmune conditions, including severe active Rheumatoid Arthritis (RA) and severe, recalcitrant Plaque Psoriasis. For severe RA, studies explored outcomes reflecting daily functioning or activity level, such as changes in swollen and tender joint counts. For Psoriasis, research explored outcomes linked to inflammatory or irritative states by measuring the extent and severity of skin lesions (PASI score).


What is Still Uncertain in the Research Landscape

While the evidence base was observed to be substantial, particularly in transplant medicine, there are areas where research indicates that certainty remains low or data are still emerging. A key limitation is that many findings are derived from combination therapies, meaning the specific contribution of Sigmasporin to the outcome can be challenging to isolate fully. For autoimmune and kidney uses, follow-up durations were limited in certain trials, meaning the long-term effects on sustained symptom control are not fully established. Furthermore, the results apply only to the populations studied and may not predict individual outcomes in daily-life settings.

Key Studies & References

  1. Efficacy and safety of cyclosporine a for patients with steroid-resistant nephrotic syndrome: a meta-analysis
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Sigmasporin (FAQ)

Q: Is Sigmasporin the same as Cyclosporine?

Sigmasporin is the brand name for a medicine containing the active substance Cyclosporine (also known as Ciclosporin). Official documentation for the drug uses both names to refer to the active therapeutic ingredient.

Q: What is the difference between Sigmasporin and other medications used for similar conditions?

Sigmasporin belongs to a specific pharmacological class known as Calcineurin Inhibitors. This class works by selectively targeting T-lymphocytes, which are white blood cells central to the immune response. Other medicines used for similar conditions may belong to different pharmacological classes with distinct ways of acting on the immune system.

Q: Do you always have to take Sigmasporin long-term?

Usage of the medicine varies depending on the medical reason it is being prescribed. Official guidance describes the use as either long-term for maintaining transplant organ acceptance, or as time-limited for certain non-transplant autoimmune conditions.

Q: Is it normal to feel nauseous when starting Sigmasporin?

Nausea and general stomach discomfort are listed among the commonly reported side effects associated with this medication in official safety documents. Concerns about side effects are generally addressed by consulting a healthcare provider.

Q: Can I take ibuprofen or acetaminophen with Sigmasporin?

Official documents caution against taking this medicine with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, and other kidney-toxic agents. This is due to the potential for an additive risk for renal toxicity (kidney damage). Any combination of medications must be managed under specialist supervision.

Q: Does Sigmasporin make you tired?

Official warnings advise caution when driving or using machines if certain neurological disturbances, which include somnolence (drowsiness), are experienced. The labeling indicates that the medicine has the potential to affect alertness based on documented neurological effects such as somnolence.

Q: What does the research say about the long-term use of Sigmasporin?

Research has explored long-term use, especially for transplant management, with studies often monitoring patient outcomes for 5 to 10 years. However, official documents note that limitations in follow-up duration for other uses mean the long-term effects on sustained symptom control are not fully established in all conditions.

Q: Is there a generic version of Sigmasporin available?

Yes, the active ingredient in Sigmasporin, Cyclosporine, is available under various brand names and is also available in generic formulations.

Q: What is the shelf life of Sigmasporin?

Official information provides specific guidance on the stability of the oral solution after the bottle has been opened. It is explicitly required that the oral solution must be discarded 60 days after the bottle is first opened.

Q: Can I take herbal supplements while on Sigmasporin?

Official regulatory documents strictly prohibit the combination with the herbal product St. John's wort. This is because it is documented to reduce the medicine's plasma levels and compromise its therapeutic effectiveness.

Q: Are headaches a common side effect of Sigmasporin?

Headaches are listed among the commonly reported side effects associated with this medication, according to official regulatory safety documents.

Q: What happens if I stop taking Sigmasporin suddenly?

Due to the medicine's potency and function, regulatory-aligned patient guidance indicates that this medication should never be stopped suddenly unless explicitly directed to do so by a qualified healthcare professional or transplant coordinator.

Q: What kind of research has been done on Sigmasporin for non-transplant uses?

Research has examined the medicine's application for certain severe autoimmune conditions. These non-transplant uses include severe active Rheumatoid Arthritis (RA) and severe, recalcitrant Plaque Psoriasis, with studies focusing on outcomes related to daily function or the severity of skin lesions.

Q: Does Sigmasporin affect my ability to drive?

Official labeling indicates that this medicine may impact the ability to drive and use machines. The official documentation indicates that exercising care may be appropriate if neurological disturbances such as confusion or dizziness are experienced.

Q: Is it true that Sigmasporin can affect gum health?

Yes, the safety profile lists Gingival Hyperplasia (gum overgrowth) as a commonly documented side effect. This is one of the safety issues that requires regular monitoring during use.

Q: Why are people often told to avoid sun exposure while taking Sigmasporin?

The use of this medicine is associated with an increased susceptibility to malignancies (cancers), including skin cancer, according to official safety documentation. The potential link between immunosuppression and risk of skin malignancies is cited in official safety documentation.

Q: If I have liver issues, can I use Sigmasporin?

Patients with severe hepatic impairment (liver issues) may still be eligible to use the medicine but may require a dosage adjustment. This is because severe liver issues can significantly increase the drug's exposure in the body, and its use is subject to specialized medical oversight.

Q: Why does the cost of Sigmasporin vary so much?

Cost variations may be linked to the existence of both brand name and generic formulations. Furthermore, the active ingredient is classified as a Narrow Therapeutic Index (NTI) medication, meaning bioequivalence and switching between products require specialized medical oversight, which can influence price and availability.

Q: Can taking Sigmasporin affect vaccinations?

Yes, official documents strictly prohibit the use of Live Vaccines. This restriction is due to the medicine's immunosuppressive effects, which create a heightened risk of clinical infection if a live vaccine is administered.

Q: How long does Sigmasporin stay in your system?

Official documents describe the drug's elimination half-life in transplant patients as approximately 11 hours. This is the time it takes for half the medicine to be cleared from the body, though the overall time it takes to fully leave the system can vary.

Q: How do the different Sigmasporin formulations (e.g., capsule vs solution) compare?

Official information states that the product is not bioequivalent across all brands and formulations (capsules, oral solution, etc.). Therefore, any change in the specific type or brand of medicine requires specialist medical supervision and dosage adjustment.

Q: What is Sigmasporin's safety classification for breastfeeding?

Official eligibility guidelines state that use is generally contraindicated or not recommended for nursing mothers. This is because the drug transfers into breast milk, which poses a potential risk to the nursing infant.

Q: How does Sigmasporin affect the immune system, generally speaking?

The medicine is definitively categorized as a powerful immunosuppressive agent. Its general purpose is to lessen the body’s innate defense reactions by selectively targeting T-lymphocytes, which are crucial white blood cells in the immune system.

Q: What is the meaning of the high-level warnings associated with Sigmasporin?

The high-level warnings emphasize risks inherent to the medicine's action of suppressing the immune system. The primary risks documented are the increased susceptibility to serious infections and the development of malignancies (cancers), which necessitate continuous monitoring.

Q: If I miss a dose of Sigmasporin, what generally happens?

Maintaining a consistent schedule is required for this medicine. Regulatory-aligned guidance indicates that if a patient misses a dose or intends to change the time of administration, a healthcare provider should be consulted.

Q: What are the official cautions for people taking Sigmasporin with high blood pressure?

Systemic Hypertension (high blood pressure) is listed as a very common side effect, and its risk is explicitly stated to be dose- and duration-dependent. Furthermore, for non-transplant uses, the medicine is contraindicated (prohibited) in patients with uncontrolled hypertension.

Q: Does Sigmasporin interact with alcohol?

Official information notes that the oral solution formulation contains alcohol (ethanol). This is a factor that should be considered for patients with liver disease or a history of alcohol abuse, as the alcohol content may worsen these conditions.

Q: How is Sigmasporin different from a steroid medication?

Sigmasporin is classified as a Calcineurin Inhibitor, a class that works specifically by targeting T-lymphocytes. This makes it distinct from other types of immunosuppressive drugs, such as steroid medications, which suppress the immune system through a different mechanism.

Q: What is the typical expectation for follow-up appointments when taking Sigmasporin?

Official safety monitoring requirements mandate the continuous checking of whole blood concentrations, renal function, blood pressure, and serum lipids. This indicates that a required regimen of regular follow-up appointments is necessary to manage the documented risks.

Q: Is it necessary to take Sigmasporin with food?

Regulatory information requires that administration of the medicine must be done on a consistent daily schedule with respect to meals. This means the relationship between when you take the medicine and when you eat must be kept the same to maintain stable systemic drug exposure.

Advertisements

How should Sigmasporin be stored and disposed of?

How to Store and Dispose of Cyclosporine (Sigmasporin)

Official regulatory guidelines mandate specific storage and disposal requirements for Cyclosporine (Sigmasporin) to maintain product stability and ensure safety.


Storage Requirements

The medicine must be stored at Controlled Room Temperature (typically 15 C to 30 C). It is essential to keep the product from freezing and not to refrigerate the oral solution, as low temperatures may cause it to become lumpy. Store the medicine away from heat, moisture, and direct light in its original, tightly closed container.

  • Stability: The oral solution must be discarded 60 days after the bottle is first opened.
  • Child Safety: Keep the product out of the reach of children; the capsule packaging is not child-resistant.

Disposal Instructions

Unused or expired Cyclosporine is classified as a hazardous drug. Do not flush the medicine down the sink or toilet. Disposal requires adherence to hazardous waste protocols, and it must be managed through an approved waste disposal firm to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sigmasporin found in:

A-Z Index: